Altimmune Inc (ALT)
1.88
+0.05 +2.73%
NASDAQ
Dec 6, 20:00
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 7.814M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -4.056 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -40.93M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -1.70K% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | 0.00% |
| Price and Valuation | |
| Market Cap | 28.84M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 2.795 |
| PE Ratio (TTM) | -- |
| Price to Book Value | 0.5839 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | 0.0021 |
| Free Cash Flow (Quarterly) | -2.436M |
| Return on Equity (TTM) | Upgrade |
View All ALT News
News
-
WireHeadlineTime (ET)
-
Globe Newswire11/21 08:00
-
SA Breaking News11/14 09:04
-
MT Newswires11/13 17:55
-
MT Newswires11/13 16:42
-
SA Breaking News11/13 16:28
-
Globe Newswire11/13 16:15
-
Yahoo11/11 05:43
-
Globe Newswire11/06 07:00
-
Yahoo11/01 14:41
-
Globe Newswire10/10 07:00
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 11/08/2019 08:30 EST | Misc | Altimmune Inc Third Quarter Earnings Conference Call in 2019 |
| 11/08/2019 | Earnings | Altimmune Inc Third Quarter Earnings in 2019 Release |
| 09/26/2019 10:00 EDT | Misc | Altimmune Inc Annual General Meeting for 2018 |
| 08/14/2019 08:30 EDT | Misc | Altimmune Inc Second Quarter Earnings Conference Call in 2019 |
| 08/14/2019 | Earnings | Altimmune Inc Second Quarter Earnings in 2019 Release |
| 05/15/2019 08:30 EDT | Misc | Altimmune Inc First Quarter Earnings Conference Call in 2019 |
| 05/15/2019 | Earnings | Altimmune Inc First Quarter Earnings in 2019 Release |
| 04/01/2019 | Misc | Altimmune Inc Annual Report in 2018 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.altimmune.com
- Investor Relations URL: http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-irhome
- HQ State/Province: Maryland
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Value
- Next Earnings Release: N/A
- Last Earnings Release: Nov. 08, 2019
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: Jan. 20, 2017
- Description: Altimmune Inc is a United States-based clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases. The firm's product candidates include NasoVAX, HepTcell, SparVax-L, NasoShield, and Oncosyn. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 1.88 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ALT Tweets Stocktwits
Advertisement
